Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions Osamu Iida, MD, Shinsuke Nanto, MD, Masaaki Uematsu,

Slides:

Advertisements

Similar presentations

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen.

Advertisements

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen.

Without prejudice Journal of Vascular Surgery

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease Yiu Che Chan, MBBS, MD, FRCS, Stephen.

Carotid artery stenting may be performed safely in patients with radiation therapy- associated carotid stenosis without increased restenosis or target.

Restenosis in gold-coated renal artery stents

Primary stenting of femoropopliteal atherosclerotic lesions using new helical interwoven nitinol stents Yiu Che Chan, MBBS, BSc, MD, FRCS, Stephen W.

EXCITE ISR Trial design: Participants with femoropopliteal in-stent restenosis were randomized to excimer laser atherectomy + adjunctive angioplasty (n.

Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions Tomoharu Dohi,

Stenting of femoropopliteal lesions using interwoven nitinol stents

First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease Johannes Lammer, MD, Marc.

Misaki M. Kiguchi, MD, MBA, Luke K. Marone, MD, Rabih A

A percutaneous arterial closure protocol can decrease complications after endovascular interventions in vascular surgery patients Philip P. Goodney,

Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease

Ali F. AbuRahma, MD, J. David Hayes, MD, Sarah K

Open bypass and endovascular procedures among diabetic foot ulcer cases in the United States from 2001 to 2010 Grant H. Skrepnek, PhD, David G. Armstrong,

Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions Takao Ohki, MD, PhD, Kimihiko.

Results of the United States multicenter prospective study evaluating the Zenith fenestrated endovascular graft for treatment of juxtarenal abdominal.

Duplex ultrasound criteria for femorofemoral bypass revision

Early duplex scanning after infrainguinal endovascular therapy

Endovascular therapy for limb salvage in a case of critical lower limb ischemia resulting from fibromuscular dysplasia Osamu Iida, MD, Shinsuke Nanto,

Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia Francesco A. Aiello, MD, Asad A.

Without prejudice Journal of Vascular Surgery

Gary R. Seabrook, MD Journal of Vascular Surgery

Mesenteric stenting for chronic mesenteric ischemia

Insulin use is associated with poor limb salvage and survival in diabetic patients with chronic limb ischemia Hasan H. Dosluoglu, MD, Purandath Lall,

Depression is associated with worse patency and recurrent leg symptoms after lower extremity revascularization Gregory S. Cherr, MD, Jiping Wang, MD,

Long-term results of direct and indirect endovascular revascularization based on the angiosome concept in patients with critical limb ischemia presenting.

Impact of cilostazol after endovascular treatment for infrainguinal disease in patients with critical limb ischemia Yoshimitsu Soga, MD, Osamu Iida,

Miguel Montero-Baker, MD, Gregory J

Clinical efficacy of endovascular therapy for patients with critical limb ischemia attributable to pure isolated infrapopliteal lesions Osamu Iida, MD,

Infrainguinal revascularizations in octogenarians and septuagenarians

Effect of perioperative complications after endovascular therapy in patients with peripheral artery disease due to femoropopliteal lesions Kei Sato,

Surgical revascularization versus endovascular therapy for chronic mesenteric ischemia: A comparative experience Marvin D. Atkins, MD, Christopher J.

Derek de Grijs, MD, Pedro Teixeira, MD, Steven Katz, MD

Infrainguinal angioplasty with drug-eluting stents and balloons

The adverse effects of race, insurance status, and low income on the rate of amputation in patients presenting with lower extremity ischemia Mohammad.

Combination therapy with warfarin plus clopidogrel improves outcomes in femoropopliteal bypass surgery patients Mario Monaco, MD, Luigi Di Tommaso, MD,

Virendra I. Patel, MD, Mark F. Conrad, MD, Christopher J

Amy N. Roach, BS, Sebastian Larion, MS, Sadaf S. Ahanchi, MD, Chad P

The number of patent tibial vessels does not influence primary patency after nitinol stenting of the femoral and popliteal arteries Jenny J. Lee, MD,

Open versus endovascular revascularization for chronic mesenteric ischemia: Risk- stratified outcomes Gustavo S. Oderich, MD, Thomas C. Bower, MD, Timothy.

Drug-eluting balloon angioplasty versus uncoated balloon angioplasty in patients with femoropopliteal arterial occlusive disease Hidde Jongsma, MD, Joost.

Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis Monika Herten, PhD, Giovanni.

Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery Yoshimitsu.

Thomas A. Simone, MD, Benjamin S. Brooke, MD, PhD, Philip P

Initial and 3-year results after subintimal versus intraluminal approach for long femoropopliteal occlusion treated with a self-expandable nitinol stent

The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé.

Stent placement for treatment of central and peripheral venous obstruction: A long-term multi-institutional experience Gustavo S.C. Oderich, MD, Gerald.

Ryan M. Svoboda, Kristina A. Giles, Samantha A. Connell, Daniel B

Reply Journal of Vascular Surgery

Three-year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive.

Intentional coverage of the left subclavian artery during endovascular repair of traumatic descending thoracic aortic transection Michele Antonello,

Impact of runoff on superficial femoral artery endoluminal interventions for rest pain and tissue loss Mark G. Davies, MD, PhD, Wael E. Saad, MD, Eric.

Predicting loss of patency after forearm loop arteriovenous graft

Santiago Chahwan, MD, M. Todd Miller, MD, John P. Pigott, MD, Ralph C

Karen J. Ho, MD, Christopher D. Owens, MD, MSc

Cassius Iyad Ochoa Chaar, MD, Michel S. Makaroun, MD, Luke K

Results of a randomized clinical trial of external beam radiation to prevent restenosis after superficial femoral artery stenting Eric Therasse, MD,

Secondary interventions following endovascular abdominal aortic aneurysm repair using current endografts. A EUROSTAR report Roel Hobo, MSc, Jacob Buth,

Donald T. Baril, MD, Luke K. Marone, MD, Justine Kim, Michael R

Gregory C. Schmieder, MD, Megan Carroll, BA, BS, Jean M. Panneton, MD

Sikandar Z. Khan, MD, Muhammad A

Results of second-time angioplasty and stenting for femoropopliteal occlusive disease and factors affecting outcomes William P. Robinson, MD, Louis L.

Ten-year technical and clinical outcomes in TransAtlantic Inter-Society Consensus II infrainguinal C/D lesions using duplex ultrasound arterial mapping.

Endovascular interventions for TASC II D femoropopliteal lesions

Endovascular brachytherapy for renal artery in-stent restenosis

Ultrasound velocity criteria for renal in-stent restenosis

J. David Neel, MD, Robin L. Kruse, PhD, Viktor Y

Prior failed ipsilateral percutaneous endovascular intervention in patients with critical limb ischemia predicts poor outcome after lower extremity bypass

Presentation transcript:

Cilostazol reduces restenosis after endovascular therapy in patients with femoropopliteal lesions Osamu Iida, MD, Shinsuke Nanto, MD, Masaaki Uematsu, MD, Takakazu Morozumi, MD, Masafumi Kitakaze, MD, Seiki Nagata, MD Journal of Vascular Surgery Volume 48, Issue 1, Pages 144-149 (July 2008) DOI: 10.1016/j.jvs.2008.02.062 Copyright © 2008 The Society for Vascular Surgery Terms and Conditions

Fig 1 Patency after endovascular therapy (primary end point) for symptomatic de novo femoropopliteal lesions compared between patients receiving cilostazol (solid circles) and ticlopidine (clear circles). Patency was evaluated by duplex ultrasonography (peak systolic velocity ratio >2.4). (A) By intention-to-treat analysis, patency rates at 12, 24, and 36 months were 87%, 82%, and 73% in the cilostazol group and 65%, 60%, and 51% in ticlopidine group (P = .013). (B) By as-treated analysis, patency rates at 12, 24, and 36 months were 87%, 82%, and 73% in the cilostazol group and 64%, 57%, and 48% in ticlopidine group (P = .0088). Journal of Vascular Surgery 2008 48, 144-149DOI: (10.1016/j.jvs.2008.02.062) Copyright © 2008 The Society for Vascular Surgery Terms and Conditions

Fig 2 Patency for the different types of stent used: nitinol stents (NI, filled symbol) vs cobalt metallic stents (Co, open symbol) compared between the cilostazol (circles) group and the ticlopidine (squares) group. Patency of nitinol stents used in the cilostazol group tended to be the highest among the groups (P = .09). Journal of Vascular Surgery 2008 48, 144-149DOI: (10.1016/j.jvs.2008.02.062) Copyright © 2008 The Society for Vascular Surgery Terms and Conditions

Fig 3 Freedom from target lesion revascularization (TLR) compared between the cilostazol (circles) group and the ticlopidine (squares) group (secondary end point). Freedom from TLR at 12, 24, and 36 months was significantly higher in the cilostazol group than in the ticlopidine group (88%, 82%, and 82% vs 73%, 70%, and 58%; P = .036). Journal of Vascular Surgery 2008 48, 144-149DOI: (10.1016/j.jvs.2008.02.062) Copyright © 2008 The Society for Vascular Surgery Terms and Conditions

Fig 4 Freedom from all adverse events (secondary end point), including death, amputation and restenosis was significantly higher at 12, 24, and 36 months in patients treated with cilostazol (circles) than in those treated with ticlopidine (squares): 77%, 72%, and 60% vs 60%, 50%, and 41% (P = .031). Journal of Vascular Surgery 2008 48, 144-149DOI: (10.1016/j.jvs.2008.02.062) Copyright © 2008 The Society for Vascular Surgery Terms and Conditions